<DOC>
	<DOC>NCT00191542</DOC>
	<brief_summary>Comparison of the effect of Atomoxetine and psychoeducation with placebo and psychoeducation after 10 weeks of treatment</brief_summary>
	<brief_title>Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Meet the criteria for ADHD of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) as well as severity criteria. Diagnosis is assessed by the investigator's clinical evaluation as well as administration of the KSADSPL structured interview. Meet a symptom severity threshold of 1.5 standard deviations above age and sex norms for their diagnostic subtype on the ADHDRSIVParent: InvestigatorAdministered and Scored (ADHDRSIVParent:Inv) This severity threshold must be met at Visit 1 and maintained at Visit 2. Be at least 7 years of age, but not yet have reached their 16th birthday prior to Visit 1, when informed consent is obtained. For female subjects of childbearing potential only, test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use a reliable method of birth control. Weigh less than 20 kg at study entry Have a documented history of Bipolar Disorder or any history of psychosis or pervasive development disorder (autistic spectrum disorder). Are pregnant or breastfeeding. Are at serious suicidal risk as assessed by the investigator. Have been treated previously for ADHD with pyschostimulants such as Methylphenidate or Ritalin</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2006</verification_date>
</DOC>